Topics

Adcs Enter The Bispecific Era

Cancer Immunotherapy Tumor Microenvironment Cell Death & Disease DNA Metabolism And Repair

ADCs enter the bispecific era as bispecific antibody-drug conjugates, or BsADCs, combine the tumor-targeting logic of antibody-drug conjugates with the dual-recognition capacity of bispecific antibodies. This field emerged from efforts to improve ADC selectivity, internalization, tumor penetration, payload delivery, and resistance management, while next-generation ADC research now includes bispecific ADCs, probody-drug conjugates, immune-stimulating antibody conjugates, degrader-antibody conjugates, and dual-payload ADCs[1][2][3].

BsADCs act by binding two tumor-associated antigens or two epitopes, increasing avidity on dual-positive cancer cells and improving payload delivery after receptor-mediated internalization. Dual-antigen targeting can improve tumor selectivity, modulate two functional pathways, and support better therapeutic precision than single-antigen recognition. Key mechanisms include antigen binding, endocytosis, linker processing, payload release, DNA damage or microtubule disruption, and pathway blockade such as EGFR/HER2-dependent inhibition of PI3K/AKT/mTOR and PD-L1 signaling in pancreatic cancer models[1][4][5][6].

Disease applications now span solid tumors and hematologic malignancies. In pancreatic cancer, an EGFR/HER2 dual-targeting lidamycin conjugate bound EGFR and HER2, entered cells by endocytosis, promoted apoptosis and G2/M arrest, inhibited proliferation, and regressed tumors in cell-line and patient-derived xenograft models. In colorectal cancer, a pCAD × CDH17 bispecific MMAE ADC showed antitumor activity in tumors expressing both antigens but not tumors expressing only one antigen. In acute myeloid leukemia, a CD33 × CD7 bispecific ADC used an AND-gated design for optimal payload delivery and improved tumor selectivity in aggressive CD33-positive/CD7-positive disease models[6][7][8].

The main gaps remain target-pair selection, antigen heterogeneity, internalization efficiency, off-target toxicity, linker-payload optimization, and clinical translation. Current evidence supports BsADCs as a rational next-generation ADC strategy, but the field still needs stronger predictive biomarkers, better understanding of tumor microenvironment interactions, optimized antibody formats, and clinical data showing whether dual targeting can consistently improve efficacy and safety over monospecific ADCs[1][2][3][4].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L089 Mitochondria-Targeted Compound Library
Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca2+ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation. MCE supplies a unique collection of 1,182 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

Signaling Pathway Targeting Libraries

89
HY-L099 Targeted Diversity Library
MCE Targeted Diversity Library contains 2,294 compounds, covering more than 1000 targets and isoforms, such as GPCRs, Ion channel, variety of kinases, etc. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. The bioactivity information of each compound has been clearly reported in the literatures. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at low cost.

General Bioactive Screening Libraries

85
HY-L023 Toxins for Antibody-Drug Conjugate Research Library
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 116 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Compound Characteristic Classified Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L196 Protein Kinase Compound Library
Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR. MCE designs a unique collection of 4,585 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.
84
HY-L129 Target Protein Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance. MCE carefully prepared a unique collection of 128 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

83
HY-L137 Molecular Glue Compound Library
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 124 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Compound Characteristic Classified Libraries

83
HY-L153 Cysteine Targeted Covalent Library
Covalent inhibitors are small molecules that can bind specifically to target proteins through covalent bonds and inhibit their biological functions. Although for a long time, covalent targeting has been playing a subordinate role in drug discovery, with an increasing number of reports on successful clinical applications of such drugs, the potential of these agents is now being acknowledged. Currently, cysteine is the most common covalent amino acid residue in a variety of covalent drugs, and various warheads have been developed that can react with cysteine, providing the key building blocks for covalent drugs to form covalent bonds. To meet the development needs of covalent inhibitors targeting cysteine, MCE has designed a unique collection of 5,267 compounds with different covalent warheads that target cysteine. The MCE Cysteine Targeted Covalent Library is designed using the following covalent warheads: Acrylamides, Propiolic acid ester, Dimethylamine functionalized acrylamides, Chloroacetamides, Acrylonitrile, 2-Cyanoacrylamide, Aziridine, Haloacetamide, etc.

Structure Classified Libraries

83
HY-L154 Cysteine Targeted Covalent Fragment Library
Covalent inhibitors are small molecules that can bind specifically to target proteins through covalent bonds and inhibit their biological functions. Although for a long time, covalent targeting has been playing a subordinate role in drug discovery, with an increasing number of reports on successful clinical applications of such drugs, the potential of these agents is now being acknowledged. Currently, cysteine is the most common covalent amino acid residue in a variety of covalent drugs, and various warheads have been developed that can react with cysteine, providing the key building blocks for covalent drugs to form covalent bonds. To meet the development needs of covalent inhibitors targeting cysteine, MCE has designed a unique collection of 3,728 fragments with different covalent warheads that target cysteine. The MCE Cysteine Targeted Covalent Fragment Library is designed using the following covalent warheads: Acrylamides, Propiolic acid ester, Dimethylamine functionalized acrylamides, Chloroacetamides, Acrylonitrile, 2-Cyanoacrylamide, Aziridine, Haloacetamide, etc. All fragments are pre-filtered with the Rule of Three restrictions which can be used for fragment-based covalent drug development.

Structure Classified Libraries Functional Fragment Libraries

83
HY-L159 Highly Selective Activators Library
Agonistic drugs activate or stimulate their receptors, triggering responses that increase or decrease cell activity. The highly selective activators can act on specific biological or molecular targets, while non-selective activators may interfere with multiple targets or targets simultaneously. The highly selective activators reduce the likelihood of these non-specific effects by targeting specific targets, making research more precise and reliable. The Highly Selective Activators Library contains 2,192 compounds, covering multiple targets and subtypes, such as GPCR protein family, Ion channel, multiple kinases, etc. The Highly Selective Activators Library is an effective tool for screening different phenotypes.
83
HY-L169 Anti-Drug-Resistant Compound Library
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important. MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

Compound Characteristic Classified Libraries

83
HY-L230 FDA Kinase Inhibitor Library
Kinases are enzymes that catalyze the addition of phosphate groups to substrate molecules, a process known as phosphorylation. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes, including cell division, metabolism, and signal transduction. The human genome encodes over 500 kinases, which collectively regulate approximately 50% of cellular functions. Due to their pivotal roles, kinases represent one of the most important target classes in drug development. Kinase inhibitors can selectively block the activity of disease-associated kinases, making them valuable therapeutics for conditions such as cancer and inflammatory diseases. FDA-approved kinase inhibitors have undergone extensive preclinical and clinical studies, demonstrating high bioactivity, favorable safety profiles, and good bioavailability, rendering them suitable for investigating new therapeutic indications.
83
HY-L256 Azide Compound Library
In modern drug discovery and chemical biology research, the azide group (-N3) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality. The MCE Azide Structural Compound Library contains 100 compounds featuring -N3 functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.

Compound Characteristic Classified Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9921 Trastuzumab emtansine
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
HER-2 Positive Breast Cancer   Metastatic Breast Cancer  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-15940 5(6)-Carboxyfluorescein
5(6)-Carboxyfluorescein (5(6)-FAM) is an amine-reactive pH-sensitive green fluorescent probe. 5(6)-Carboxyfluorescein (5(6)-FAM) can be used to label proteins, peptides and nucleotides. 5(6)-Carboxyfluorescein can be used for the detection of tumour areas in vivo.
Fluorescent Dye  
5
HY-N0401A (Z)-Ligustilide
(Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6. (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer.
Bacterial   Estrogen Receptor/ERR   FATP  
Infection   Metabolic or Endocrine Disease   Breast Cancer  
5
HY-K0202K IP/Co-IP Kit (Protein A/G Magnetic Beads)

MCE IP/Co-IP Kit (Protein A/G Magnetic Beads) can be used for protein purification, IP, Co-IP of target proteins or their protein complexes.

Protein Biology Immunoprecipitation Kit

5
HY-B0459 Scopine
Scopine is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine can be used in targeted therapy research for brain gliomas.
Drug Metabolite  
Cancer   Neurological, Eye or Ear Disease  
2
HY-P4094 CTP
CTP (cardiac targeting peptide) can transduce cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be reversibly linked (e.g. via enolases, thiol groups) to cargo (e.g. miRNAs) for delivery specifically to cardiomyocytes over all other organs.
Others  
Cardiovascular Disease  
2
HY-P10055A PSMA targeting peptide TFA
PSMA targeting peptide TFA (PSMA-1 TFA) is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells.
PSMA  
Cancer  
1
HY-N0381 Maackiain
Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever。
Keap1-Nrf2   p38 MAPK   NOD-like Receptor (NLR)   NF-κB   mTOR   Monoamine Oxidase   Nuclear Factor of activated T Cells (NFAT)   PKC   Apoptosis   Pyroptosis   Autophagy   Dengue Virus  
Flavivirus Infection   Alzheimer's Disease   Osteoporosis  
1
HY-P99101 Vobramitamab
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma.

Species: Human

ADC Antibodies  
Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99854 Disitamab
Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985).

Species: Human

EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
1
HY-N3005 Britannin
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics.
Apoptosis   Autophagy   NOD-like Receptor (NLR)   Pyroptosis  
Prostate Cancer   Liver Cancer   Depression   Autoimmune Disease   Digestive System Inflammation  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-171191 REGN5093-M114
REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase inhibits the proliferation of NSCLC cells, exhibits antitumor efficacy in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig (HY-P990073) and the tubulin-inhibiting linker-payload (HY-148528).
Antibody-Drug Conjugates (ADCs)   Microtubule/Tubulin   c-Met/HGFR  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-78931G Boc-Dap-NE (GMP)
Boc-Dap-NE (GMP) is Boc-Dap-NE (HY-78931) produced by using GMP guidelines. Boc-Dap-NE is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
ADC Linkers  
Cancer  
/
HY-15579BG MMAF sodium (GMP)
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
Microtubule/Tubulin   ADC Payloads  
Cancer  
/
HY-15578G McMMAF (GMP)
McMMAF GMP is a GMP grade McMMAF (HY-15578). McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a agent-linker for antibody-drug conjugates (ADC). McMMAF is uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active agent.
Drug-Linker Conjugates for ADC  
Cancer  
/
HY-P990974 Bezeotermin alfa
HY-P990974 is an BMP-6-targeting Fusion Protein.
TGF-β Receptor  
Inflammation or Immune System Disease  
/
HY-166975 Polysarcosine 100
Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-122973 7-Oxodehydroabietinol
7-Oxodehydroabietinol is a selective inhibitor targeting the human herpesvirus HHV-2. 7-Oxodehydroabietinol can be used in anti-herpesvirus drug development to target HHV-2 infection.
HSV  
HSV Infection  
/
HY-W1050525 Fmoc-Val-Ala-Gly
Fmoc-Val-Ala-Gly (compound 58a) is a cleavable ADC linker, can be conjugated to the antibody Trastuzumab (HY-P9907) to form an antibody-drug conjugate (ADC).
ADC Linkers  
/
HY-P4088 LyP-2
LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics.
Others  
Cancer  
/
HY-I1129 Fmoc-3VVD-OH-d8
Fmoc-3VVD-OH-d8 is a deuterium labeled Fmoc-3VVD-OH (HY-78921). Fmoc-3VVD-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Isotope-Labeled Compounds   ADC Linkers  
Cancer  
/
HY-D2967 Golgi-NO
Golgi-NO is a Golgi-targeted fluorescent probe for nitric oxide (NO) (Ex/Em: 560 nm/589 nm). Golgi-NO exhibits excellent selectivity for various potential interfering substances. Golgi-NO can be used to study the function of NO within the Golgi apparatus in disease models such as Alzheimer's disease (AD).
Fluorescent Dye  
Alzheimer's Disease  
/
HY-137228 4-Nitrophenylmaltohexaoside
4-Nitrophenylmaltohexaoside is a chromogenic substrate targeting α-amylase.
Biochemical Assay Reagents  
/
HY-D2228 IR-7
IR-7 is a mitochondria-targeted heptamethylindocyanine dye, and can used for cancer study.
Fluorescent Dye  
/
HY-182981A Mannose-PEG2000-Biotin
Mannose-PEG2000-Biotin is a conjugate composed of mannose, PEG chains, and biotin. Mannose-PEG-Biotin combines the targeting recognition ability of mannose with the high affinity of biotin to bind avidin/link avidin, and is used for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-P11883 GGGFG
GGGFG (Compound 20-2) is a pentapeptide consisting of glycine-glycine-glycine-phenylalanine-glycine, which can be used for synthesis of linker-payload of antibody-drug conjugates (ADCs).
/
HY-B1161S Methoprene-d7
Methoprene-d7 is the deuterium labeled Methoprene. Methoprene, an insect juvenile growth hormone mimic, is a growth-regulating insecticide that manifests its toxicity to target organisms by acting as a juvenile hormone agonist.
Isotope-Labeled Compounds  
/
HY-P11807 DArg-DLys-DTyr-DTyr-Gly-DTrp
DArg-DLys-DTyr-DTyr-Gly-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-W010450S Thymine-d4
Thymine-d4 is the deuterium labeled Thymine. Thymine is one of the four nucleobases in the nucleic acid of DNA and can be a target for actions of 5-fluorouracil (5-FU) in cancer treatment, with a Km of 2.3 μM.
Isotope-Labeled Compounds   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P3441 3BP-4089
3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research.
FAP  
Cancer  
/
HY-P991668 PF-06688992 Antibody
PF-06688992 Antibody is an antibody targeting GD3. PF-06688992 Antibody can be used for the synthesis of the antibody-drug conjugate PF-06688992 (HY-P991668).

Species: Human

ADC Antibodies  
Cancer  
/
HY-P11805 Gly-Gly-DTyr-Gly-Gly
Gly-Gly-DTyr-Gly-Gly is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P11295 Fmoc-GGFG-PAB-PNP
Fmoc-GGFG-PAB-PNP is an ADC linker used in the synthesis of antibody-drug conjugates (ADC).
ADC Linkers  
Cancer  
/
HY-166973 Polysarcosine 20
Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-182981 Mannose-PEG1000-Biotin
Mannose-PEG1000-Biotin is a conjugate composed of mannose, PEG chains, and biotin. Mannose-PEG-Biotin combines the targeting recognition ability of mannose with the high affinity of biotin to bind avidin/link avidin, and is used for applications such as constructing targeted drug delivery systems and nanoparticle modification.
Biochemical Assay Reagents  
/
HY-121260 Cryptopine
Cryptopine is a non-narcotic isoquinoline alkaloid. Cryptopine can reduce the activities of glutathione S-transferase (GST) and glutathione reductase (GR), depletes intracellular glutathione levels, stimulates lipid peroxidation, and induces cytotoxicity by disrupting the cellular defense system. Cryptopine binds stably to key targets of liver cancer and also exhibits anthelmintic activity against Dactylogyrus intermedius. Cryptopine can be used in studies related to liver cancer and Dactylogyrus intermedius infection.
Insecticide   Glutathione S-transferase   Glutathione Reductase (GR)  
Liver Cancer   Insecticide  
/
HY-P11804 DTyr-Gly-DTyr-Gly
DTyr-Gly-DTyr-Gly is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-P11806 DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp
DLeu-DTyr-Gly-DTrp-Gly-DTyr-DTrp is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-131833G Fmoc-Gly-Gly-Phe-OH (GMP)
Fmoc-Gly-Gly-Phe-OH GMP is a GMP grade Fmoc-Gly-Gly-Phe-OH (HY-131833). Fmoc-Gly-Gly-Phe-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-13631DS1 DXd-d2
DXd-d22 (Exatecan derivative for ADC-d2) is the deuterated-labeled DXd (HY-13631D). DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
Isotope-Labeled Compounds   Topoisomerase   ADC Payloads  
Breast Cancer   Prostate Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer  
/
HY-B0546AS Procaine-d4 hydrochloride
Procaine-d4 (hydrochloride) is the deuterium labeled Procaine hydrochloride. Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.
Isotope-Labeled Compounds   Histone Demethylase   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease  
/
HY-108953 (S)-Quinolactacine A
(S)-Quinolactacine A is a quinolone inhibitor that targets TNF production.

Source: Penicillium sp. EPF-6

Others  
Inflammation or Immune System Disease  
/
HY-P991971 ONCR-201
ONCR-201 (PG-101) is a fully human monoclonal antibody targeting epithelial membrane protein 2 (EMP2). ONCR-201 is applicable to research related to breast cancer, ovarian cancer, and endometrial cancer.

Species: Human

Others  
Breast Cancer   Ovarian Cancer   Endometrial Cancer  
/
HY-19792S Mertansine-13C,d3
Mertansine-13C,d3 (DM1-13C,d3) is the 13C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).
Isotope-Labeled Compounds   ADC Payloads   Microtubule/Tubulin  
/
HY-D2912 Cys-shift probe-1
Cys-shift probe-1 (compound 13) is a potent Cys-shift probe. Cys-shift probe-1 can improve the ion mobility of labeled peptides and be used in protein analysis.
Biochemical Assay Reagents  
/
HY-P991970 REGN3124
REGN3124 is a fully human antibody with binding to EGFRvIII. REGN3124 forms REGN3124-PBD via conjugation to pyrrolobenzodiazepine linker-payload SG-3249. REGN3124 can be used for the research of glioblastoma multiforme.

Species: Human

EGFR  
/
HY-19792S2 Mertansine-d3
Mertansine-d3 (DM1-d3) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).
Isotope-Labeled Compounds   ADC Payloads   Microtubule/Tubulin  
/
HY-114816S N-butyryl-L-Homoserine lactone-d5
N-butyryl-L-Homoserine lactone-d5 is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa.
Isotope-Labeled Compounds   ADC Linkers   Bacterial  
Inflammation or Immune System Disease  
/
HY-W243303J Poly(acrylic acid) (MW 250000)
Poly(acrylic acid) (MW 250000) is a synthetic cationic electrolyte containing abundant carboxyl groups (-COOH), which exhibits excellent water absorption and retention properties and is often cross-linked to form hydrogels. Poly(acrylic acid) (with a molecular weight of 250,000). Poly(acrylic acid) (MW 250000) can be used as a non-collagenous analog in the biomimetic mineralization research of type I collagen. Poly(acrylic acid) (MW 250000) has pH responsiveness and biocompatibility and is often used as a drug carrier, surface modifier and functional material.
Biochemical Assay Reagents  
Cancer  
/
HY-N144101 SARS-CoV MPro-IN-2
SARS-CoV MPro-IN-2 (compound 15) is a potent inhibitor of SARS-CoV-2 Mpro with an IC50 value of 72.07 nM. The main protease (Mpro) of the virus as the major enzyme processing viral polyproteins contributes to the replication and transcription of SARS-CoV-2 in host cells, and has been characterized as an attractive target in agent discovery. SARS-CoV MPro-IN-2 has the potential for the research of COVID-19.
SARS-CoV  
/
HY-D3457 Tracer AL244
Tracer AL244 is a BODIPY-based fluorescent tracer and also a TRIM21 binder. Tracer AL244 enables evaluation of TRIM21 target binding in both intact and permeabilized cells.
E1/E2/E3 Enzyme   Fluorescent Dye  
/
HY-166974 Polysarcosine 150
Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research.
Biochemical Assay Reagents  
/
HY-B1057S2 Nefopam-d3
Nefopam-d3 is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells.
β-catenin  
Neurological, Eye or Ear Disease  
/
HY-P991973 HuL001
HuL001 is a specific monoclonal antibody targeting ENO1. HuL001 remodels the tumor microenvironment by inhibiting cancer-associated fibroblasts, thereby suppressing the progression of multiple myeloma. HuL001 can be used for research on cancers such as colorectal cancer, pancreatic ductal adenocarcinoma, and myeloma.

Species: Human

Enolase  
Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Ductal Adenocarcinoma  
/
HY-W007324R Maleimide (Standard)
Maleimide (Standard) is the analytical standard of Maleimide (HY-W007324). This product is intended for research and analytical applications. Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes.
Reference Standards   ADC Linkers   Biochemical Assay Reagents  
/
HY-113593 GSK1360707
GSK1360707 is a triple uptake inhibitor targeting nitrogen and olefin substitution reactions.
Biochemical Assay Reagents  
/
HY-N2625 Harmalol
Harmalol is a β-carbazine alkaloid with anticancer activity. Harmalol binds and interacts with several natural and synthetic nucleic acids of different motifs, including DNA and RNA. In addition, harmalol has an apoptosis-inducing effect on human hepatoma cells in vitro.
Apoptosis  
Cancer  
/
HY-133540G Maleimide-DOTA (GMP)
Maleimide-DOTA (Maleimido-mono-amide-DOTA) (GMP) is Maleimide-DOTA (HY-133540) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Maleimide-DOTA is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer   Inflammation or Immune System Disease  
/
HY-D2614 ICG PEG2000 biotin
ICG PEG2000 biotin is a fluorescent dye composed of Indocyanine green (ICG) (HY-D0711), PEG and biotin. Indocyanine green provides it with fluorescent labeling function, PEG enhances its biocompatibility and stability, and biotin can bind to target molecules containing streptavidin to achieve targeted imaging or targeted delivery (Ex/Em=785/813 nm).
Fluorescent Dye  
/
HY-W013973R p-Terphenyl (Standard)
p-Terphenyl (Standard) is the analytical standard of p-Terphenyl. This product is intended for research and analytical applications. p-Terphenyl is a specialty material, and may be used in ionized radiation detectors, nonpolar laser dye, and single molecule optical probe of scanning near-field microscopy. p-Terphenyl can be used to synthesis p-Terphenyl derivatives, for the research of cancer and inflammatory diseases.
Reference Standards   Biochemical Assay Reagents  
Cancer   Inflammation or Immune System Disease  
/
HY-145399S AZ14170133-d5
AZ14170133-d5 (SG 3932-d5) is the deuterium labeled AZ14170133 (HY-145399). AZ14170133 (SG 3932) is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. AZ14170133 can be used to synthesis antibody-drug conjugate (ADC).
Isotope-Labeled Compounds   Topoisomerase   Drug-Linker Conjugates for ADC  
/
HY-129300S Prosulfocarb-d7
Prosulfocarb-d7 (S-Benzyl dipropylthiocarbamate-d7) is deuterium labeled Prosulfocarb. Prosulfocarb is a herbicide with a rapidly growing use trend. Prosulfocarb is used in winter cereals to help address the problem of increasing biotic resistance of weeds to certain pesticides. Environmental and food effects of prosulfocarb have been observed, and its transfer pattern from target crops to non-target areas has been studied. The volatility effect of prosulfocarb is an important factor explaining the inefficiency of isolated area contamination and marginal protection against residue spread.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-W034918R Docosanedioic acid (Standard)
Docosanedioic acid (Standard) is the analytical standard of Docosanedioic acid (HY-W034918). This product is intended for research and analytical applications. Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
ADC Linkers   Reference Standards   PROTAC Linkers  
/
HY-P10888 GPC3 targeting peptide 1
GPC3 targeting peptide 1 is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
Glycoprotein VI  
Cancer  
/
HY-N15345 Menominin A
Menominin A is a cyclic peptide identified from the freshwater sponge-associated cyanobacterium Nostoc sp., exhibiting cytotoxic properties. It displays antiproliferative activity against the ovarian cancer cell line OVCAR3, with an IC50 value of 3.1 μM. Menominin A holds promise for research in the field of anticancer therapeutics.

Source: Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607

Others  
/
HY-135928 Biotin-C2-S-S-pyridine
Biotin-C2-S-S-pyridine is a cleavable ADC linker. Biotin-C2-S-S-pyridine can be used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-78932G Dap-NE hydrochloride (GMP)
Dap-NE hydrochloride (GMP) is Dap-NE hydrochloride (HY-78932A) produced by using GMP guidelines. Dap-NE hydrochloride is an intermediate used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-P9994 Pertuzumab zuvotolimod
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research.
Antibody-Drug Conjugates (ADCs)   EGFR   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease  
/
HY-78921AG Fmoc-3VVD-OH (GMP)
Fmoc-3VVD-OH (GMP) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-145397S (4-NH2)-Exatecan-d5
(4-NH2)-Exatecan-d5 is a deuterated labeled (4-NH2)-Exatecan. (4-NH2)-Exatecan (compound A), a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs).
Isotope-Labeled Compounds   Topoisomerase   ADC Payloads  
Cancer  
/
HY-10331S Regorafenib-d3
Regorafenib-d3 (BAY 73-4506-d3) is a deuterium labeled Regorafenib (HY-10331). Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.
VEGFR   Autophagy   PDGFR   Raf   RET  
Cancer  
/
HY-D2170 AF488 streptavidin
AF488 streptavidin is a fluorescently labeled streptavidin. AF488 streptavidin is a streptavidin conjugated to Alexa Fluor 488, with 4 fluorophores per protein molecule, enabling stoichiometric fluorescent labeling of cell surface targets. AF488 streptavidin can form a complex with biotinylated E07 aptamer to stain cells expressing EGFR, and the staining is reversible after treatment with mA9 detoxifying oligonucleotides (Ex/Em = 470/520 nm).
Fluorescent Dye  
/
HY-P990988 Efgitasialase alfa
HY-P990988 is an Sialidase-2-targeting Fusion Protein.
Others  
Inflammation or Immune System Disease  
/
HY-136432A Mc-Gly-Gly-Phe-Gly-PAB-OH TFA
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) TFA is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-176415S Cys-MC-GGFG-Dxd-d5
Cys-MC-GGFG-Dxd-d5 is the deuterium labeled Cys-MC-GGFG-Dxd (HY-176415). Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan (HY-13631E). Cys-MC-GGFG-Dxd is a linker-toxin building block in antibody-drug conjugates (ADCs) used to link antibody Cys residues to cytotoxic drugs. Cys-MC-GGFG-Dxd can be used in cancer research.
Isotope-Labeled Compounds   Drug-Linker Conjugates for ADC  
/
HY-D2615 ICG PEG5000 biotin
ICG PEG5000 biotin is a fluorescent dye composed of Indocyanine green (ICG) (HY-D0711), PEG and biotin. Indocyanine green provides it with fluorescent labeling function, PEG enhances its biocompatibility and stability, and biotin can bind to target molecules containing streptavidin to achieve targeted imaging or targeted delivery (Ex/Em=785/813 nm).
Fluorescent Dye  
/
HY-15583S Auristatin F-d8
Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
Isotope-Labeled Compounds   ADC Payloads   Microtubule/Tubulin  
Cancer  
/
HY-D2441 TAT-PEG-Cy3
TAT-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, Cell membrane penetrating peptide (TAT) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. TAT-PEG-Cy3 can be used for cell targeted delivery and biological imaging.
Fluorescent Dye  
Cancer  
/
HY-15582S Auristatin E-d8
Auristatin E-d8 is the deuterium labeled Auristatin E (HY-15582). Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids.
Isotope-Labeled Compounds   ADC Payloads   Microtubule/Tubulin  
/
HY-P99630 Gancotamab antibody
Gancotamab antibody (MM-302) is a HER2-targeted antibody with antitumor activity.

Species: Human

EGFR  
HER-2 Positive Breast Cancer  
/
HY-P99035 Naptumomab
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer  
/
HY-161022S1 FL118-C3-O-C-amide-C-NH2-d5 formate
FL118-C3-O-C-amide-C-NH2-d5 formate is a deuterium labeled FL118-C3-O-C-amide-C-NH2 formate. FL118-C3-O-C-amide-C-NH2 formate is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
Isotope-Labeled Compounds   ADC Linkers  
Cancer  
/
HY-158253 Lectin from Helix pomatia, biotin conjugate
Helix pomatia lectin, biotin conjugate, is a carbohydrate-binding protein that is widely found in fungi, plants, and animals. Helix pomatia lectin, biotin conjugate is commonly used for characterizing, imaging, or targeting glycoconjugates, and is also a very useful tool for glycomics analysis.
Biochemical Assay Reagents  
/
HY-P992127 Renditatug
Renditatug (BAT8008 Antibody) is an antibody targeting TROP2. Renditatug can be used for the synthesis of ADC BAT8008. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TROP2   ADC Antibodies  
Breast Cancer   Pancreatic Cancer  
/
HY-W000423G DBCO-amine (GMP)
DBCO-amine (GMP) is a GMP grade DBCO-amine (HY-W000423). DBCO-amine is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. DBCO-amine is used in the synthesis of antibody-drug conjugates (ADCs).
Biochemical Assay Reagents  
Cancer  
/
HY-W034918 Docosanedioic acid
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
ADC Linkers   PROTAC Linkers  
Cancer  
/
HY-P991342 CQY684
CQY684 (PCA062 antibody) is a monoclonal antibody targeting CDH3/P-cadherin, which locks P-cadherin in an X-dimer conformation and enhances the stability of this adhesion structure. CQY684 induces P-cadherin phosphorylation and promotes its dissociation from the cytoplasmic region of P-cadherin. As an endocytosis inducer and lysosome-targeting agent, CQY684 facilitates the internalization of the P-cadherin-CQY684 complex and improves the turnover efficiency of P-cadherin. CQY684 serves as a platform for the delivery of intracellular anticancer compounds, which is achieved through the targeted lysosomal transport of the antibody-P-cadherin complex. CQY684 is applicable to the research of breast cancer, esophageal cancer, and head and neck cancer.

Species: Human

Cadherin  
Breast Cancer   Esophageal Cancer  
/
HY-P991742 LY4101174 Antibody
LY4101174 Antibody (15A7.5; ETx-22 Antibody) is an ADC antibody that serves as the antibody component of LY4101174. LY4101174 is an antibody-drug conjugate (ADC) targeting nectin-4 and exhibits broad-spectrum anti-tumor activity. LY4101174 Antibody is applicable to research related to solid tumors.

Species: Human

ADC Antibodies  
Cancer  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P10501A FRα-targeting peptide C7 TFA
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment.
Antifolate  
Cancer  
/
HY-176559 LacNAc-VC-PAB-MMAE
LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab (HY-P9907) by WT Endo-S2.
Drug-Linker Conjugates for ADC  
Cancer  
/
HY-P10945 FAP targeting peptide for FXX489
FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand.
Radionuclide-Drug Conjugates (RDCs)   FAP  
Cancer  
/
HY-P11069 Kidney-targeting peptide
Kidney-targeting peptide is a kidney-targeting peptide (KTP). Kidney-targeting peptide significantly enhances the renal targeting ability of Isoquercitrin (HY-N1445). Kidney-targeting peptide can be used in diabetic nephropathy research.
Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-145627 Ozuriftamab vedotin
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities.
Antibody-Drug Conjugates (ADCs)   Microtubule/Tubulin  
/
HY-P3441A 3BP-4089 TFA
3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research.
FAP  
Cancer  
/
HY-D2910 Ox4
Ox4 is a selective covalent modifier targeting Methionine residues. Ox4 is promising for research of protein functionalization, antibody-drug conjugate (ADC) synthesis, and proteome-wide identification of reactive methionine sites.
Others  
/
HY-W1124925 DOTA-GPC3 targeting peptide 2
DOTA-GPC3 targeting peptide 2 (Sequence 30) is a RDC peptide targeting GPC3, with Kd of 0.3 nM. DOTA-GPC3 targeting peptide 2 is composed of DOTA and GPC3 targeting peptide 2. DOTA-GPC3 targeting peptide 2 can be labeled with radioactive elements.
Radionuclide-Drug Conjugates (RDCs)   Glycoprotein VI  
Cancer  
/
HY-117371 Hemiasterlin
Hemiasterlin ((-)-Hemiasterlin) is an antimitotic marine natural product with potent anticancer effects. Hemiasterlin can be used as a cytotoxic payload (ADC Cytotoxin) in antibody-drug conjugates (ADCs).

Source: marine sponges

ADC Payloads  
Cancer  
/
HY-136432 Mc-Gly-Gly-Phe-Gly-PAB-OH
Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
ADC Linkers  
Cancer  
/
HY-P99453 Azintuxizumab
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin.

Species: Human

ADC Antibodies  
Cancer  
/
HY-P99718 Lupartumab
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 (HY-P99719).

Species: Human

ADC Antibodies  
Cancer  
/
HY-42709 Z-Val-Ala-OH
Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1].
Amino Acid Derivatives  
Cancer  
/
HY-N4067 Isochenodeoxycholic acid
Isochenodeoxycholic acid (isoCDCA) is a FXR agonist. Isochenodeoxycholic acid activates the activity of FXR and induces the mRNA expression of FXR target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction.

Source: bile acids

FXR   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-W010162 H-Ala-Ala-OH
H-Ala-Ala-OH is a substrate of human intestinal oligopeptide transporter (PEPT1/SLC15A1), with an IC50 of 0.25 mM and an EC50 of 0.08 mM against human PEPT1. When used as a dipeptide linker in antibody-drug conjugates (ADCs) loaded with glucocorticoid receptor regulator payloads, H-Ala-Ala-OH enables efficient intracellular payload release.
Amino Acid Derivatives  
/
HY-P99034 Moxetumomab
Moxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.

Species: Human

CD22  
Leukemia/Lymphoma/Myeloma  
/
HY-P10888A GPC3 targeting peptide 1 TFA
GPC3 targeting peptide 1 TFA is a GPC3 targeting peptide, with a Kd value of 0.23 nM.
Glycoprotein VI  
Cancer  
/
HY-13442AS Eribulin-d3 mesylate
Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer.
Microtubule/Tubulin   Apoptosis  
Cancer  
/
HY-P1449 Boc-Gly-Gly-Phe-Gly-OH
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
ADC Linkers  
Cancer  
/
HY-W009274 N-Acetylmuramic acid
N-acetylmuramic acid is a component of the bacterial cell wall peptidoglycan, essential for maintaining cell shape and integrity. N-acetylmuramic acid inhibits spore germination by inhibiting a coat-associated hexosaminidase and a core enzyme. N-acetylmuramic acid is required by Bacteroides forsythus for proliferation and the maintenance of its cell shape. N-Acetylmuramic acid inhibits the p38 MAPK/NF-κB signaling pathway, and exhibits anti-inflammatory activity. N-Acetylmuramic acid is orally active.
p38 MAPK   NF-κB   Bacterial  
Infection   Inflammation or Immune System Disease  
/
HY-123687 DBCO-Sulfo-NHS ester sodium
DBCO-Sulfo-NHS ester sodium is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). DBCO-Sulfo-NHS ester (sodium) is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
ADC Linkers  
Cancer  
/
HY-177442 DS-3939a
DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers.
Antibody-Drug Conjugates (ADCs)   Mucin   Topoisomerase   Apoptosis  
/
HY-170554 ABBV-706
ABBV-706 is a SEZ6-targeted topoisomerase 1 inhibitor Antibody-Drug Conjugates (ADCs), which is composed of the Linker-Payload conjugation (HY-148820) and the Anti-SEZ6 Antibody (SC17) (HY-P991041). ABBV-706 can inhibit cancer cells proliferation and induce DNA damage and G2/M arrest. ABBV-706 exhibits high efficacy against small cell lung cancer (SCLC), neuroendocrine tumors (NENs) and central nervous system (CNS) tumors.
Antibody-Drug Conjugates (ADCs)   Topoisomerase   DNA/RNA Synthesis  
CNS Neoplasm   Small Cell Lung Cancer  
/
HY-177434 Precemtabart tocentecan
Precemtabart tocentecan (Precem-TcT; M 9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody-drug conjugate (ADC). Precemtabart tocentecan consists of a tumor-specific anti-CEACAM5 monoclonal antibody Precemtabart (HY-P990940), a highly hydrophilic and stable cleavable β-glucuronide linker, and a topoisomerase 1 inhibitor payload Exatecan (HY-13631), and the drug-linker conjugate for ADC is Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179). Precemtabart tocentecan inhibits the growth of CEACAM5-positive cancer cells. Precemtabart tocentecan exhibits significant antitumor activity in CEACAM5-expressing xenograft models. Precemtabart tocentecan can be used for the study of CEACAM5-expressing advanced solid tumors, especially mCRC.
Antibody-Drug Conjugates (ADCs)   Transmembrane Glycoprotein   Topoisomerase  
Cancer  
/
HY-W007324 Maleimide
Maleimide can be used for production of antibody-drug conjugate (ADC) which is used in cancer research. Maleimide also be leveraged for the preparation of fluorogenic probe, which is mainly used for the specific detection of thiol analytes.

Source: Streptomyces showdoensis

ADC Linkers  
Cancer  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P99054 Tusamitamab
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542).

Species: Human

Transmembrane Glycoprotein   ADC Antibodies  
Gastric Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-P99971 Gemtuzumab
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein  
Cancer  
/
HY-P990673 Vandortuzumab
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein   Mitosis  
Castration-Resistant Prostate Cancer  
/
HY-13631DS DXd-d5
DXd-d5 is a deuterium labeled DXd. DXd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) .
Topoisomerase   ADC Payloads  
Cancer  
/
HY-P70371 Importin alpha-1/KPNA2 Protein, Human (His)
Importin alpha-1/KPNA2 is essential for nuclear protein import, acting as an adapter for the nuclear receptor KPNB1. It directly binds the substrate to the nuclear localization signal to form a complex that docks with the nuclear pore complex mediated by KPNB1. Importin alpha-1/KPNA2 Protein, Human (His) is the recombinant human-derived Importin alpha-1/KPNA2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P70837 KPNB1 Protein, Human (His)
KPNB1 is a key player in nuclear protein import, cooperating with adapter proteins such as importin-alpha to recognize nuclear localization signals (NLS) in cargo substrates. In autonomous mode, it acts as its own NLS receptor, facilitating docking of the import/substrate complex to the nuclear pore complex (NPC) via KPNB1. KPNB1 Protein, Human (His) is the recombinant human-derived KPNB1 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P76220 CD3 zeta/CD247 Protein, Human (His)
CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (His) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-His labeled tag.

Species: Human; Source: E. coli

CD Antigens T Cell CD Proteins CD3ζ

/
HY-P75364 CDC37 Protein, Human (sf9, GST)
The CDC37 protein is a co-chaperone that binds multiple kinases and promotes their interaction with the Hsp90 complex, resulting in stability and enhanced activity. CDC37 Protein, Human (sf9, GST) is the recombinant human-derived CDC37 protein, expressed by Sf9 insect cells , with C-GST labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P75362 CDC37 Protein, Mouse (sf9, His-GST)
The CDC37 protein is a co-chaperone that binds to kinases and promotes their interaction with Hsp90 complexes, thereby stabilizing and activating them. It inhibits the ATPase activity of HSP90AA1. CDC37 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived CDC37 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Species: Mouse; Source: Sf9 insect cells

/
HY-P75363 CDC37 Protein, Mouse (sf9)
The CDC37 protein is a co-chaperone that binds to kinases and promotes their interaction with Hsp90 complexes, thereby stabilizing and activating them. It inhibits the ATPase activity of HSP90AA1. CDC37 Protein, Mouse (sf9) is the recombinant mouse-derived CDC37 protein, expressed by Sf9 insect cells, with tag free.

Species: Mouse; Source: Sf9 insect cells

/
HY-P80960 CDC37 Antibody
CDC37 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CDC37.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P810682 Phospho-MYPT1 (Thr853) Antibody (YA9940)
Phospho-MYPT1 (Thr853) Antibody (YA9940) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MYPT1 (Thr853).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80962 Phospho-CDC37 (Ser13) Antibody (YA219)
Phospho-CDC37 (Ser13) Antibody (YA219) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CDC37 (Ser13).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P810683 Phospho-MYPT1 (Thr696) Antibody (YA9941)
Phospho-MYPT1 (Thr696) Antibody (YA9941) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-MYPT1 (Thr696).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P86347 MYPT1 Antibody (YA6039)
MYPT1 Antibody (YA6039) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MYPT1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80961 Phospho-CDC37 (Ser13) Antibody
Phospho-CDC37 (Ser13) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-CDC37 (Ser13).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P80962A Phospho-CDC37 (Ser13) Antibody (YA219)(PBS only)
Phospho-CDC37 (Ser13) Antibody (YA219) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CDC37 (Ser13).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P810725 PEX7 Antibody (YA9969)
PEX7 Antibody (YA9969) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to PEX7 Antibody.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85576 Phostensin Antibody (YA5268)
Phostensin Antibody (YA5268) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Phostensin.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86580 Phospho-CDC37(Ser13) Antibody (YA6272)
Phospho-CDC37(Ser13) Antibody (YA6272) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-CDC37(Ser13).

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-K0231 Anti-c-Myc Affinity Gel

MCE Anti-c-Myc Affinity Gel can be used for the detection and purification of c-Myc fusion expressed proteins, and immunoprecipitation (IP) experiments to detect the expression of recombinant proteins in target cells.

Protein Biology Protein Purification Agarose Beads

/
HY-K0357 Mouse Mature B Cell Negative Selection Kit

MCE Mouse Mature B Cell Negative Selection Kit enables the efficient isolation of mature B cells from single-cell suspensions prepared from mouse spleen, lymph nodes, or bone marrow. The principle involves using biotin-labeled monoclonal antibodies to label non-target cells (non-B cells), followed by the removal of these non-target cells through streptavidin-labeled magnetic beads, achieving the selective isolation of mouse mature B cells.

Cell Biology Cell Isolation

/
HY-K0359 Human Neutrophil Negative Selection Kit

MCE Human Neutrophil Negative Selection Kit can isolate neutrophils from fresh peripheral blood. The principle involves using biotin-labeled monoclonal antibodies to label non-target cells, followed by the removal of these non-target cells through streptavidin-labeled magnetic beads, achieving the selective isolation of human neutrophils.

Cell Biology Cell Isolation

/
HY-K0361 Mouse Pan B Cell Negative Selection Kit

MCE Mouse Pan B Cell Negative Selection Kit enables the efficient isolation of total B cells from mouse spleen, lymph nodes, bone marrow, or peritoneal lavage fluid. The principle involves using biotin-labeled monoclonal antibodies to label non-target cells (non-B cells), followed by the removal of these non-target cells through streptavidin-labeled magnetic beads, achieving the selective isolation of mouse B Cells.

Cell Biology Cell Isolation

/
HY-K2033 OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research.

Cell Biology Cell Culture Cell Transfection

/
HY-K2034 OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells)

MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies.

Cell Biology Cell Culture Cell Transfection

/
HY-KD1004A Vari Fluor 4-colour Multiple Fluorescent Staining Kit-1 (For all samples)
Multiplex immunohistochemistry is also known as Tyramide Signal Amplification (TSA, Tyramide dignal amplification). It has been used for more than 20 years as an enzymatic assay for high-density in situ labelling of target proteins or nucleic acids by horseradish peroxidase (HRP). The method is based on multiple cis-immunostaining with tyramide signal amplification, which allows the detection of multiple target sites in cell or tissue samples in situ, and elucidation of their interaction mechanism through the study of the combination and positional relationship of these target sites.

Protein Biology Multiple Fluorescent Staining

/
HY-KD1005 Vari Fluor 5-colour Multiple Fluorescent Staining Kit ((For mouse samples)

MCE offers a wide range of multiplex fluorescence kits for simultaneous detection of up to six targets to maximise customer satisfaction.

Multiple Fluorescent Staining

/
HY-KE7049 Sge I

Sge I restriction enzyme recognizes and cleaves DNA targets containing 5-methylcytosine on one or both DNA strands, and cuts best at 37℃.

Molecular Biology Restriction Endonuclease

/

Keywords

bispecific ADCs | antibody-drug conjugates | BsADCs | dual-antigen targeting | cancer therapeutics | linker-payload | tumor heterogeneity